Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Serum IL-17F does not predict poor response to IM IFNß-1a in relapsing-remitting MS.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Serum IL-17F does not predict poor response to IM IFNß-1a in relapsing-remitting MS.
Serum IL-17F does not predict poor response to IM IFNß-1a in relapsing-remitting MS. Neurology. 2012 Aug 07; 79(6):531-7.
View in:
PubMed
subject areas
Adjuvants, Immunologic
Adult
Biomarkers
Cohort Studies
Female
Humans
Injections, Intramuscular
Interferon beta-1a
Interferon-beta
Interleukin-17
Male
Multiple Sclerosis, Relapsing-Remitting
Treatment Outcome
authors with profiles
Robert Axtell